

Row ID	REC Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Participants Recruited	Reason For Closure Of Trial
1	13/EM/0340	117243	A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion	Number Agreed	1	1	Date Agreed	12/11/2020	1	12/11/2020	1	Recruitment Finished
2	18/LO/0396	238968	A PHASE 1B STUDY EVALUATING RO7082859 IN COMBINATION WITH RITUXIMAB (R) OR OBINUTUZUMAB (G) PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN PARTICIPANTS WITH RELAPSED REFRACTORY FOLLICULAR LYMPHOMA (R/R FL) OR IN PARTICIPAN	Number Agreed	2	2	Date Agreed	20/11/2020	0	20/11/2020	0	Recruitment Finished
3	19/SC/0416	269256	A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)	Number Agreed	4	4	Date Agreed	30/11/2020	2	30/11/2020	2	Recruitment Finished
4	18/EM/0091	242354	A Randomized, Double-Blind, Placebo Controlled Study To Evaluate Efficacy And Safety Of NEFECON In Patients With Primary IGA Nephropathy At Risk Of Progressing To End-Stage Renal Disease (NeflgArd)	Number Agreed	2	2	Date Agreed	04/01/2021	3	04/01/2021	3	Recruitment Finished
5	18/LO/0034	238090	An open-label randomized, parallel-group, multicenter, observational trial to evaluate the safety and efficacy of edoxaban tosylate in children from 38 weeks gestational age to less than 18 years of age with cardiac disease at risk of thromboembolic	Number Agreed	2	2	Date Agreed	17/02/2021	2	17/02/2021	2	Recruitment Finished
6	19/EM/0057	257429	A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic N	Number Agreed	5	5	Date Agreed	19/02/2021	7	19/02/2021	7	Recruitment Finished
7	18/SS/0120	233867	A Randomized, Open-Label Phase II/III Study with Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects with Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy	Number Agreed	5	5	Date Agreed	24/02/2021	0	24/02/2021	0	Recruitment Finished
8	18/NW/0514	249725	SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity	Number Agreed	17	17	Date Agreed	19/03/2021	15	19/03/2021	15	Recruitment Finished

Row ID	REC Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Participants Recruited	Reason For Closure Of Trial
9	19/SC/0622	270469	A Phase 1b Open-label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma	Number Agreed	2	2	Date Agreed	19/03/2021	0	19/03/2021	0	Recruitment Finished
10	19/SW/0093	260867	A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 with Background Treatment in Subjects with Lupus Nephritis	Number Agreed	4	4	Date Agreed	29/03/2021	0	29/03/2021	0	Recruitment Finished
11	18/EM/0229	250101	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE-CONTROL STUDY OF THE EFFICACY AND SAFETY OF SPARSENTAN FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY	Number Agreed	20	20	Date Agreed	28/04/2021	7	28/04/2021	7	Recruitment Finished
12	19/YH/0097	261131	Peanut Oral Immunotherapy Study of Early Intervention for Desensitization	Number Agreed	5	5	Date Agreed	01/05/2021	1	01/05/2021	1	Recruitment Finished
13	18/NW/0694	248847	A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (	Number Agreed	4	4	Date Agreed	05/05/2021	1	05/05/2021	1	Recruitment Finished
14	19/LO/0343	255538	The PRECISE Protocol: Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization	Number Agreed	4	4	Date Agreed	11/05/2021	4	11/05/2021	4	Recruitment Finished
15	20/LO/0944	1003371	SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast Cancer	Number Agreed	4	4	Date Agreed	18/06/2021	2	18/06/2021	2	Recruitment Finished
16	19/YH/0400	271539	A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiomer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone System Inhibitor (RAASI) Medications for the Treatment of	Number Agreed	6	6	Date Agreed	24/06/2021	0	24/06/2021	0	Recruitment Finished

Row ID	REC Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
17	20/SC/0111	276734	DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexameth	Number Agreed	3	3	Date Agreed	28/06/2021	5	28/06/2021	5	Recruitment Finished
18	18/LO/1290	249002	A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Seropositive Donors (D+)	Number Agreed	1	1	Date Agreed	30/06/2021	3	30/06/2021	3	Recruitment Finished
19	16/EE/0514	207302	Randomized, Double-Blind Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)	Number Agreed	2	2	Date Agreed	15/08/2021	14	15/08/2021	14	Recruitment Finished
20	20/ES/0031	276439	Protocol I8F-MC-GPGN The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)	Number Agreed	10	10	Date Agreed	16/09/2021	12	16/09/2021	12	Recruitment Finished